Can physical activity help to maintain cognitive functioning and psychosocial well-being among breast cancer patients treated with chemotherapy? A randomised controlled trial: study protocol by Kajal Gokal (1253433) et al.
Gokal et al. BMC Public Health  (2015) 15:414 
DOI 10.1186/s12889-015-1751-0STUDY PROTOCOL Open AccessCan physical activity help to maintain cognitive
functioning and psychosocial well-being among
breast cancer patients treated with chemotherapy?
A randomised controlled trial: study protocol
Kajal Gokal1,2*, Fehmidah Munir1,2, Deborah Wallis1,2, Samreen Ahmed3, Ion Boiangiu3 and Kiran Kancherla3Abstract
Background: Evidence suggests chemotherapy treatment for breast cancer is associated with side effects such as
cognitive impairment in domains of memory, attention, concentration and executive function. Cognitive impairments
reported by patients have been associated with higher levels of emotional distress. To date, intervention studies to
alleviate cognitive impairment associated with chemotherapy have focused on psycho-educational techniques
or cognitive training. Studies have not yet considered physical activity as a potential for alleviating cognitive
problems. Physical activity interventions are reported to be effective in alleviating emotional distress and fatigue
in those with breast cancer. They have also been reported to improve cognitive functioning in the elderly, in
those suffering with dementia and in children. We propose that physical activity could also help to alleviate
cognitive impairments in women diagnosed with breast cancer. The study has been designed using a recently
developed taxonomy of behaviour change techniques to reliably report the content of the intervention to allow
future replication.
Method: This study will deliver a home-based moderate intensity walking intervention to women diagnosed with
breast cancer mid-way through their chemotherapy treatment and will compare them to patients receiving usual
care alone. The primary outcome measure for this intervention is changes in an objective measure of memory
assessed using the Digit Span. Secondary outcome measures include: objective measures of executive function;
attention; visual spatial skills; self report cognitive function; self-report fatigue; anxiety; depression; mood and
self-esteem. As emotional distress has been associated with self-reporting of cognitive problems, this intervention
will further test whether emotional distress mediates between the amount of walking undertaken during the
intervention period and levels of self-reported cognitive functioning.
Discussion: The development of an effective intervention for preventing difficulties in emotional and cognitive
functioning of cancer patients’ post-treatment will help to guide health care professionals to improve patients’
overall quality of life. It will also provide direction for future research, ultimately to improve the day to day functioning
of breast cancer survivors.
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Breast cancer is one of the most frequently diagnosed
cancers in the UK [1]. Between 15% to 75% of patients
treated by chemotherapy experience problems with their
cognitive functioning as well as physical and emotional
side effects [2,3]. Multiple cross-sectional and longitu-
dinal studies over the last decade have found associa-
tions between chemotherapy and cognitive impairments,
both subjectively reported and objectively measured, in a
proportion of breast cancer patients and survivors
[4-10]. Commonly reported cognitive impairments in-
clude difficulties with memory, attention, information-
processing speed and executive function [11,12]. Studies
suggest that around 71% of patients report problems
with memory and 64% report difficulties with concentra-
tion [13,14]. In addition, patients receiving chemotherapy
were 2.25 times more likely to show cognitive decline fol-
lowing chemotherapy in comparison with the control
group [13]. The effects of chemotherapy on cognitive func-
tion among breast cancer patients can be long-term with
impairments evident between 4 months to 20 years post-
treatment [15-19]. Cognitive decline following chemother-
apy for breast cancer can have a profound negative impact
on patients’ overall quality of life [13,15,20,21].
Evidence suggests that cognitive problems are more
frequently reported by patients than that objectively
measured using neuropsychological assessments. Litera-
ture suggests that subjective reporting and objective
measurements of cognitive decline are not associated
with one another [5,6,9,10,22-27] but both are associated
with poorer functional outcomes and psychosocial well-
being, which may be a predisposing risk factor for devel-
oping cognitive impairment following chemotherapy in
those with breast cancer. [5,6,13,20,22,23,25,26,28-34].
The above studies suggest the need for evidence-based
interventions to prevent cognitive decline experienced
by breast cancer patients during chemotherapy. How-
ever, very few interventions have been implemented to
address cognitive difficulties and have yielded mixed re-
sults. For example, Poppelreuter et al. [35] found no
intervention effects through the implementation of cog-
nitive training strategies whereas Von Ah et al. [36], who
also used cognitive training, reported improvements in
self-reported cognitive functioning, better mental health
and quality of life outcomes. Ferguson et al. [37] imple-
mented a cognitive behavioural therapy intervention and
found no significant effect on self-reported cognitive
function [37]. Schuurs et al. [38] delivered a psycho-
education programme on cognitive strategies by using
goal setting and problem solving techniques. They found
positive improvements in the management of objective
and subjective cognitive function, psychosocial distress
and social functioning in patients with a range of cancer
diagnoses [38].The interventions discussed above were implemented
between 12 to 8 months after the completion of treat-
ment. However, evidence suggests that patients report
difficulties with cognitive functioning half way through
their treatment [39,40]. Evidence suggests that inter-
ventions to manage the side effects of chemotherapy
would be beneficial to patients mid way through
treatment as 75% of patients experience cognitive de-
cline during treatment with 35% of patients continu-
ing to report cognitive problems post-treatment [41].
Therefore, more efforts should be made towards pre-
venting cognitive problems during treatment when it
is most prevalent.
The benefits of physical activity among cancer patients
are well documented with regards to managing treat-
ment related symptoms such as fatigue, regaining phys-
ical functioning, improving quality of life [42,43] and for
improving physical functioning and fitness for breast
cancer patients [44-51]. A meta-analysis of 28 studies
revealed positive effects of exercise on cancer related
fatigue both during and after treatment [52]. Physical ac-
tivity reduced distress and improved fatigue and energy
levels at three month follow up [51-53]. Physical activity
rehabilitation has also shown to improve levels of anx-
iety for those affected by breast cancer [54]. Evidence
demonstrates promising effects of low to moderate levels
of physical activity as a protective strategy for preventing
cognitive impairment in healthy individuals, children
and the elderly [55-59]. In light of this evidence we hy-
pothesise that moderate levels of physical activity may
also help in protecting breast cancer patients against
chemotherapy-induced cognitive impairment. Hospital-
based and/or supervised interventions can restrict par-
ticipation as patients undergoing chemotherapy are
often busy with treatment schedules, are unwell or have
limited access to exercise facilities due to transportation
or scheduling difficulties [44]. Therefore, home-based in-
terventions which do not restrict participation may be
more feasible and increase adherence.
To summarise, there is good evidence illustrating the
benefits of physical activity rehabilitation for cancer pa-
tients. However, the effects of physical activity on cogni-
tive functioning for those diagnosed with cancer have
not yet been examined. Current studies implementing
physical activity as a form of rehabilitation for breast
cancer have focused upon the benefits it has on physical
fitness, quality of life, fatigue and emotional distress.
Very little research has been conducted to explore the
effects of physical activity upon cognitive functioning in
breast cancer patients. Therefore, the current interven-
tion aims to investigate the effects of a self-prescribed
moderate intensity walking on cognitive functioning and
emotional well-being of adjuvant and neo-adjuvant
breast cancer patients.
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Objectives/hypothesis
The primary aim of the study is to investigate the effective-
ness of a home-based moderate intensity walking interven-
tion on reducing cognitive impairment of breast cancer
patients receiving chemotherapy. Our primary hypothesis
is that women who complete the physical activity interven-
tion will demonstrate less impairment in memory in com-
parison to women in the non-intervention group. Our
secondary hypotheses are that the intervention group will
perform better than the control group on objective and
subjective measures of cognitive function, and will report
better quality of life outcomes than the control group. Fur-
thermore, within the intervention group, emotional well-
being will mediate between physical activity level and level
of subjectively reported and objectively tested impairment
in memory, attention and concentration.
Design
The study is a randomised controlled trial comparing
the home based walking intervention group with care as
usual control group. Outcomes will be assessed at two
time points: mid-way through chemotherapy (pre-
intervention) and after the completion of chemotherapy
(post-intervention). All participants will also complete out-
come measures prior to receiving chemotherapy to famil-
iarise them with study materials, study setting and the
researcher.
Recruitment
Sixty two females with a primary diagnosis of breast can-
cer will be recruited from the Leicester Royal Infirmary
(31 participants per group). Patients who have been diag-
nosed, are waiting to begin adjuvant or neo adjuvant
chemotherapy and are considered fit to take part in mod-
erate intensity exercise by their oncologist will be invited
to participate in the study by the researcher. Oncologists
will subjectively assess patients’ suitability for the study
based upon their medical history and physical presenta-
tion during the consultation. Those interested in partici-
pating then meet with the researcher who will provide
them with an information sheet and explain the study in
further detail. Those participants who show interest are
then followed up a week later at which point they are
asked to complete a consent form. Participants will be
assessed using objective measures of cognitive functioning
in a small room near the waiting area. They will also
complete a series of self-report questionnaires in the com-
fort of their own homes and return them using the pre-
paid envelope provided.
Inclusion criteria
The researcher will assess patients to ensure they meet
the following inclusion criteria: to be female; aged 18–75at diagnosis; have a primary diagnosis of stage I to III
breast cancer; receiving chemotherapy and are able to
speak and read English.
Exclusion criteria
Patients will not be eligible for the intervention if they
meet the following exclusion criteria: previously diagnosed
with cancer; those who currently exceed the recommended
guidelines of 30 minutes of moderate intensity exercise five
times a week; breast cancer is a secondary diagnosis and
have a current psychiatric disorder.
Randomisation
Eligible participants will be block randomised using four
blocks to ensure equal numbers of patients in both
groups as recruitment will be staggered. Within each
group of four patients, two will be allocated to the inter-
vention group and two to the control group at time two
(mid way through chemotherapy). There is no masking
of participants or the research team.
Intervention
In line with previous literature [60] the intervention will
consist of 12 weeks of home-based moderate intensity
walking compared with usual care alone. The researcher
will provide patients with an intervention booklet which
will include: guidance and recommendations to ensure
adherence to the intervention; tips and encouragement
outlining the benefits of walking; and a diary to keep a
log of walking duration and intensity.
In line with recommended guidelines [61], participants
will be asked to exercise for 30 minutes five times a
week at moderate intensity (defined as walking at a brisk
pace). Participants will be encouraged by the researcher
to gradually increase walking duration from 10 to 30 mi-
nute bouts through the course of the intervention and
will be asked to make weekly goals outlining intended
exercise intensity, duration and timing (exactly when
they intend to exercise). They will be encouraged to re-
flect upon their achievements or shortfalls from the pre-
vious week and to take these into consideration by
modifying their goals to ensure they are realistic and
achievable. They will also be asked by the researcher to
take their chemotherapy schedule into consideration, in
order to ensure that they do not over exert themselves
or set unrealistic goals during weeks in which they will
be receiving treatment. This information will also be
presented in the walking booklet. Pedometers will be
given to the intervention group at the start of the inter-
vention so that they can be used to measure daily step
count and to provide patients with immediate feedback
and motivation. Relevant behaviour change taxonomies
[62] have been applied to this design in order to allow
accurate, reliable replication (Table 1).
Table 1 Definitions of behaviour taxonomy [51] and application to intervention
Behaviour change technique
number and label
Definition of BCT Materials Summary (use of technique in intervention)
Social support
1. Social support (unspecified) Advise on, arrange or provide social support
or non-contingent praise or reward for the
behaviour.
Intervention booklet Participants received intervention booklets
outlining the benefits of walking during
treatment, advising them to increase levels
of walking and encouraging them to walk
with friends and family.
Feedback and monitoring
11. Self-monitoring behaviour Establish a method for the person to
monitor and record the behaviour as part
of a behaviour change strategy.
Pedometer, intervention
booklet & walking diary
Patients were asked to keep a daily record of
the number of steps taken alongside the
intensity and duration of their walking
Repetition and substitution
29. Graded tasks Set easy-to-perform tasks, making them
increasingly difficult, but achievable, until
behaviour is performed.
Intervention booklet &
walking diary
Patients were encouraged to set weekly goals
and to gradually increase the number of steps
taken week by week. They were asked to
challenge themselves with each week but also
set realistic/achievable goals whilst taking their
chemotherapy schedules into consideration.
Goals and planning
61. Goal setting (behaviour) Set or agree to set a goal defined in terms
of the behaviour to be achieved.
Walking diary Patients were asked to set specific weekly step
count goals stating when and how many
steps they intend to take
65. Action planning Prompt detailed planning of performance
of the behaviour (must include at least
one of context, frequency, duration and
intensity). Context may be environmental
(physical or social) or internal (physical,
emotional or cognitive).
Walking diary Patients were encouraged to set weekly plans
outlining the amount of walking they intend
to do each day of the week. Action plans
included the duration, intensity, day of the
week and time of day they aim to complete
their walking.
Comparison of outcomes
72. Persuasive source Present verbal or visual communication
from a credible source in favour of or
against the behaviour.
Intervention booklet &
verbally
Each patient was presented with an intervention
booklet stating the benefits of walking which
were adapted from credible sources. The
patients’ consultant also verbally recommended
and encouraged patients to participate in the
physical activity involved in the study.
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The researcher will recruit participants, collect cognitive
and psychosocial data at pre and post-intervention and
facilitate the delivery of the physical activity intervention.
Initially, consenting participants will be asked by the re-
searcher to complete a self-report cognitive functioning
questionnaire, a battery of objective tests of cognitive
impairment and a questionnaire pack assessing quality
of life and emotional well-being pre-chemotherapy to
allow familiarisation with the researcher and research
materials. They will be asked to wear ActiGraph GT3X+
accelerometers for 10 hours a day for 7 days for a
measure of habitual walking after the familiarisation
assessment [63]. These data will be collected prior to
receiving chemotherapy.
After completing two cycles of chemotherapy, partici-
pants will be asked to complete the same measures
again at the clinic. Patients will then be randomised to
either the intervention or control group following theprocedures outlined above. The walking intervention
starts after 2 cycles of treatment in line with recom-
mendations from oncologists who suggests that the
intervention will be better received by patients after
they have had 2 cycles of chemotherapy and understand
what they are facing with regard to treatment side ef-
fects. The intervention group will be asked to commit
to the 12 week walking intervention and will be pro-
vided with a booklet outlining the amount of walking
they should take part in alongside guidance and tips on
how to incorporate this into their daily routines. The
intervention group will also be asked to commit to a
minimum of 150 minutes of moderate intensity walking
per week for the duration of the 12 week intervention,
in line with recommended guidelines [61]. They will be
told how to monitor their own intensity levels and will
be encouraged to aim to walk at moderate levels of in-
tensity for 150 minutes a week for the duration of the
intervention. Walking schedules will be self-prescribed
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they begin by completing 10 minutes of walking at any
one time and then steadily increase the duration of
walking to 30 minutes. Participants will be provided
with a pedometer for the duration of the intervention
and will be asked to log their walking for the 12 week
period. Those randomised to the control group will
continue to receive usual care alone.
Post-intervention (after the completion of 6 cycles of
chemotherapy), all participants will be asked to wear the
accelerometer for a further 10 hours a day for 7 days.
In addition, they will be asked to complete the same
questionnaires and neuropsychological tests as those
completed at pre-chemotherapy and mid way through
chemotherapy. At the end of the study the control groupRecruit
Familiarisation
chemothe
Pre-intervention
time one (mid-
chemothe
Randomi
Intervention group
(12 week physical
activity)
Post-inter
assessment,
(post-chemo
Figure 1 Flow diagram illustrating study methods.will receive the intervention booklet (see Figure 1 for
flow chart of study methods).
Measures of physical activity
Accelerometers (motion sensors which detect accelera-
tions produced by the human body), will be worn by all
participants for 10 hours a day for 7 days at baseline and
post-intervention to assess habitual physical activity [63].
Pedometers will be worn by participants randomised to
the intervention group for 10 hours a day for the dur-
ation of the twelve week intervention in order to record
frequency of steps taken. They will also complete the
Borg Rating of Perceived Exertion Scale [64] and The
Talk Test [65] to subjectively monitor the intensity of
their walking during the intervention.ment
session (Pre-
rapy)
assessment,
way through
rapy)
sation
Control group
(usual care alone)
vention
time two
therapy)
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All outcome measures will be completed at three time
points: baseline (familiarisation), mid way through
chemotherapy (pre-intervention) and after the comple-
tion of chemotherapy (post-intervention). All outcome
measures have been validated in this population.
Objective measures of cognitive functioning
The Stroop test [66] will be used to measure executive
function. Working memory will be tested using forwards
and backwards digit span as used in the Wechsler Adult
Intelligence Scale-III [67]. Sustained attention will be
measured using a computerised version of the Sustained
Attention to Response Task [68]. Visuospatial skills will
be measured using the WAIS Block Design subset as
used in the Wechsler Adult Intelligence Scale-III [67].
Subjective measure of cognitive functioning
The Cognitive Failures Questionnaire [69] is a 25 item
questionnaire which will be used to assess the primary
outcome measure of perceived cognitive function. The
questionnaire will ask participants to reflect on minor
mistakes made across a one month time frame. Re-
sponses are measured on a five-point Likert scale ran-
ging from ‘very often’ to ‘never’.
Subjective measures of emotional wellbeing
Anxiety and depression will be measured using the 14
items Hospital Anxiety and Depression Scale [70]. Fa-
tigue will be measured using The Functional Assessment
of Cancer therapy-Fatigue [71]. Self esteem will be mea-
sured using the Self-Esteem Scale [72]. The rating scale
requires participants to indicate how they feel in relation
to a series of 10 statements. Emotional Distress will be
measured using the shortened version of Profile of
Mood States [73]. Participants will first be asked to
complete questions regarding their anxiety and depres-
sion, followed by self-esteem, fatigue, perceived cognitive
function and lastly mood.
Additional information collected at baseline
Demographic and cancer diagnosis data will be collected
from all participants at baseline. Participants will be
asked to state the average number of hours they
spend exercising in an average week before involve-
ment in the study using the General Practioner’s Activity
Questionnaire.
Sample size
Sample size for the study was calculated based upon pre-
viously published data [37,38] and Cohen’s Power Primer
[74]. According to a prospective calculation, for a re-
peated measures ANOVA, 26 participants per group are
required to detect a large effect size with power of 0.80and α set at .05. It is reasonable to assume a large effect
size in this population based upon previous research
[37,38] and their memory performance on the digit span.
Allowing for 20% attrition due to withdrawal and illness
we aim to recruit 31 patients per group.
Statistical analyses
Quantitative data will be entered into Statistical Package
for the Social Sciences (SPSS) and intention to treat ana-
lysis will be used in line with the CONSORT statement.
To test the effectiveness of the physical activity inter-
vention on cognitive function, a series 2x2 mixed
ANCOVAs will be carried out controlling for age and
menopausal status (controlling for natural differences
in cognitive function associated with age and meno-
pausal status). Participant group (intervention or control)
will be entered as the between subjects factor and time
(pre-intervention and post-intervention) will be entered
as the within subjects factor. In addition, to test the ef-
fectiveness of the intervention on quality of life and mea-
sures of well-being another series of 2x2 mixed measures
ANOVA will be carried out between the intervention
group and control group. Post-hoc analysis will be car-
ried out using a series of t-tests to check for differences
between the intervention and control group. Lastly, to
test whether emotional distress mediates between
amount of physical activity (duration of walking and
steps taken) and self-report cognitive functioning for the
intervention group, a series of mediation analyses will be
carried out using regression analyses.
Ethics
Written informed consent will be gained by all patients
and GPs will be informed of their participation within
the study. The study has been granted ethical approval
by the National Health Service, local ethics board for
the Leicester Royal Infirmary and by Loughborough
University’s ethics committee.
Discussion
Cognitive difficulties associated with chemotherapy in
adjuvant and neo-adjuvant breast cancer patients have
been well established in research but rarely addressed
through the implementation of interventions. As the
number of breast cancer survivors increases each year
research has become more focused upon developing ef-
fective interventions to aid transition back to everyday
functioning (post-treatment). This intervention has been
developed with the aim of managing cognitive difficulties
following treatment which often affect patients for years
after completion. Cognitive difficulties experienced by
patients following the completion of treatment have
been reported to challenge their abilities to return to
work, in turn lowering levels of self-esteem further.
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insight into treatment for cognitive difficulties experi-
enced by breast cancer patients as a result of chemother-
apy which is an essential element of their treatment.
Findings will provide healthcare professionals with guid-
ance for additional care both during and after the com-
pletion of treatment and help improve current services.
It will also help direct future research to improve the
ongoing well-being of breast cancer survivors.
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